---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-21-100827"
form_type: "8-K"
ticker: "CYRX"
cik: "0001124524"
company_name: "Cryoport, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:13:29.254590+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cryoport Q2 revenue $56.2M (+498% YoY); record trials, positive adjusted EBITDA

## Summary
- Revenue $56.2M, up 498% YoY; organic growth 55%; Biopharma/Pharma up 431%.
- Net loss $5.4M vs $5.8M loss a year ago; net loss per share $0.16 vs $0.15.
- Adjusted EBITDA $5.9M vs ($2.5M) loss; gross margin 45.2% vs 54.6%.
- Supporting 561 clinical trials and 8 commercial therapies; acquired F-airGate and CTSA in Q2.
- Cash $349.4M after public offering; expects up to 9 MAA/BLA filings in H2 2021.

## SEC filing metadata
- accession: 0001104659-21-100827
- form_type: 8-K
- ticker: CYRX
- cik: 0001124524
- company_name: Cryoport, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124524/000110465921100827/0001104659-21-100827-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124524/000110465921100827/tm2124288d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-21-100827
- JSON: https://secwatch.observer/filing/0001104659-21-100827.json
- Plain text: https://secwatch.observer/filing/0001104659-21-100827.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.